News
Combining epigenetic cancer medications may have benefit for colorectal cancers and other tumor types
Tuberculosis is an ancient problem. Modern technology is helping solve it.
Van Andel Institute announces 2024 Public Lecture Series
Supporting a shared mission
Tuberculosis is an ancient problem. Modern technology is helping solve it.
Supporting a shared mission
How a ‘blockbuster’ treatment for diabetes and obesity might slow or stop Parkinson’s
‘A Grand Plan' for achieving breakthroughs and improving health
Combining epigenetic cancer medications may have benefit for colorectal cancers and other tumor types
Van Andel Institute announces 2024 Public Lecture Series
Cure Parkinson's and Van Andel Institute fund Phase 2 clinical trial of dapansutrile for Parkinson’s
Structural study points the way to better malaria drugs
We’re here to help you tell your story.
Van Andel Institute is home to experts in a range of fields, including epigenetics, neurodegeneration, metabolism, structural and cellular biology, and K–12 STEM education.
The Institute’s Communications and Marketing Department assists journalists with information about the groundbreaking research happening at VAI. We can arrange interviews with VAI scientists and provide supporting materials, such as fact sheets, photographs and b-roll video to support the production of news packages. For press inquiries, please reach out to us at [email protected] or submit an inquiry below.
Media contacts
Beth Hinshaw, M.S.
Director, Communications & Marketing
616.234.5519
[email protected]
Zane McMillin
Content Specialist, Communications & Marketing
[email protected]